Evaluation of the LncRNA TMPO AS-1 Expression Level in Breast Cancer Tissues in Comparison with Paired Normal Marginal Tissues

Niknam, Saman; Zarredar, Habib; Asvadi, Tooraj; Asadi, Milad; Zafari, Venus; Aligholipour Maleki, Raheleh; Shanehbandi, Dariush; Hashemzadeh, Shahryar

doi:10.30476/mejc.2025.105196.2229

Evaluation of the LncRNA TMPO AS-1 Expression Level in Breast Cancer Tissues in Comparison with Paired Normal Marginal Tissues

Document Type : Original Article(s)

Authors

Saman Niknam ¹

Habib Zarredar ¹

Tooraj Asvadi ¹

Milad Asadi ²

Venus Zafari ²

Raheleh Aligholipour Maleki ¹

Dariush Shanehbandi ³

Shahryar Hashemzadeh ¹

¹ Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

² Department of Basic Oncology of Health Institute of Ege University, Izmir, Turkey

³ Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

https://doi.org/10.30476/mejc.2025.105196.2229

Abstract

Background: Breast malignancy is a major public health problem and one of the prevalent cancers, which leads to death in women all around the world. Long non-coding RNAs (lncRNAs) are widely studied in the pathogenesis of malignancies. Previous studies have confirmed the correlation of lncRNAs and the cellular development and growth of breast malignancy. The present study aimed to evaluate the expression level of long non-coding RNATMPO antisense RNA 1 (LncRNA TMPO AS-1) in breast cancer tissues and compare it with paired normal marginal tissues.
Method: 50 breast cancer patients were included in this case-control study and tumor tissues and healthy marginal tissues were collected during surgery. Total RNAs were extracted from the normal and cancerous tissues, and after quality control cDNA was synthesized. The TMPO AS-1 expression level was determined by quantitative polymerase chain reaction (qPCR). The gene expression level and their relationships with the patient’s clinicopathological characteristics were analyzed using appropriate statistical tests.
Results: TMPO Antisense RNA 1(TMPO-AS1) is significantly high expressed in breast cancer tissues compared with normal peripheral tissues (P-value <0.0001, fold change: 1.16). Among the 40 patients exposed to chemotherapy drugs 5-Fluorouracil (5FU) and doxorubicin, the TMPO-AS1 expression level was significantly decreased as compared with the 10 patients unexposed to chemotherapy (P < 0.0001, fold change: 0.11). Lymph node metastatic patients (29 positive patients, 21 negative patients) showed high TMPO-AS1 expression level than negative lymph nodes metastasis patients (P = 0.0012, fold change = 1.161).
Conclusion: We demonstrated that TMPO-AS1 is highly expressed and its up-regulation correlates with the pathogenesis and tumorigenesis of breast cancer.

Highlights

Habib Zarredar (google scholar)

Milad Asadi (google scholar)

Keywords

Breast cancer

TMPO AS-1

Biomarkers

Prognoses

Subjects

Cancer Biology/Genetics

How to cite this article:

Niknam S, Zarredar H, Asvadi T, Asadi M, Zafari V, Aligholipour Maleki R, et al. Evaluation of the LncRNA TMPO AS-1 expression level in breast cancer tissues in comparison with paired normal marginal tissues. Middle East J Cancer. 2026; 17(2): 97-105. doi: 10.30476/mejc.2025. 105196.2229.

1.Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study. Asian Pac J Cancer Prev. 2019;20(7):2015-20. doi: 10.31557/APJCP.2019.20.7.2015. PMID: 31350959; PMCID: PMC6745227.
2.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac. 21492. Erratum in: CA Cancer J Clin. 2020;70(4):313. doi: 10.3322/caac.21609. PMID: 30207593.
3.Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E. Molecular classification of breast carcinoma: From traditional, old-fashioned way to a new age, and a new way. J Breast Health. 2015;11(2):59-66. doi: 10.5152/tjbh.2015.1669. PMID: 28331693; PMCID: PMC5351488.
4.Goldoost S, Zarredar H, Asadi M, Shirvaliloo M, Raeisi M. Expression and promoter methylation of mitogen-activated protein kinase 1 in tumor and marginal cells of breast cancer. Breast Dis. 2023; 42(1):437-45. doi:10.3233/BD-230001. PMID:381 43331.
5.Viale G. The current state of breast cancer classification. Ann Oncol. 2012 Sep;23 Suppl 10:x207-10. doi: 10.1093/annonc/mds326. PMID: 22987963.
6.Aftabi Y, Ansarin K, Shanehbandi D, Khalili M, Seyedrezazadeh E, Rahbarnia L, et al. Long non-coding RNAs as potential biomarkers in the prognosis and diagnosis of lung cancer: A review and target analysis. IUBMB Life. 2021;73(2):307-27. doi: 10.1002/iub.2430. PMID: 33369006.
7.Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023;12(10):11149-65. doi: 10.1002/cam4.5698. PMID: 36807772; PMCID: PMC10242329.
8.Zhang L, Wang G, Chen S, Ding J, Ju S, Cao H, et al. Depletion of thymopoietin inhibits proliferation and induces cell cycle arrest/apoptosis in glioblastoma cells. World J Surg Oncol. 2016;14(1):267. doi: 10.1186/s12957-016-1018-y. PMID: 27756319; PMCID: PMC5069786.
9.Brachner A, Foisner R. Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biology. Adv Exp Med Biol. 2014;773:143-63. doi: 10.1007/978-1-4899-8032-8_7. PMID: 24563347; PMCID: PMC43 33762.
10.Peric-Hupkes D, van Steensel B. Role of the nuclear lamina in genome organization and gene expression. Cold Spring Harb Symp Quant Biol. 2010;75:517-24. doi: 10.1101/sqb.2010.75.014. PMID: 21209388.
11.Capo-chichi CD, Cai KQ, Smedberg J, Ganjei-Azar P, Godwin AK, Xu XX. Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin J Cancer. 2011;30(6):415-25. doi: 10.5732/cjc.010.10566. PMID: 21627864; PMCID: PMC3941915.
12.Liu G, Yang H, Cao L, Han K, Li G. LncRNA TMPO-AS1 promotes proliferation and invasion by sponging miR-383-5p in glioma cells. Cancer Manag Res. 2020;12:12001-9. doi: 10.2147/CMAR. S282539. PMID: 33262650; PMCID: PMC7696628.
13.Mitobe Y, Ikeda K, Sato W, Kodama Y, Naito M, Gotoh N, et al. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer. Cancer Sci. 2020;111(7):2440-50. doi: 10.1111/cas.14498. PMID: 32437068; PMCID: PMC7385350.
14.Huang W, Su X, Yan W, Kong Z, Wang D, Huang Y, et al. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. Prostate. 2018;78(16): 1248-61. doi: 10.1002/pros.23700. PMID: 30105831.
15.Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K, et al. ESR1-stabilizing long noncoding RNA TMPO-AS1 promotes hormone-refractory breast cancer progression. Mol Cell Biol. 2019;39(23):e00261-19. doi: 10.1128/MCB. 00261-19. PMID: 31501276; PMCID: PMC6851347.
16.Osielska MA, Jagodziński PP. Long non-coding RNA as potential biomarkers in non-small-cell lung cancer: What do we know so far? Biomed Pharmacother. 2018;101:322-33. doi: 10.1016/j.biopha.2018.02.099. PMID: 29499406.
17.Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z, Zhang LW. Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 2016;20(11):2285-95. PMID: 27338053.
18.Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 2017;16(1):98. doi: 10.1186/s12943-017-0666-z. PMID: 28587642; PMCID: PMC5461634.
19.Gang X, Yuan M, Zhang J. Long non-coding RNA TMPO-AS1 promotes cervical cancer cell proliferation, migration, and invasion by regulating miR-143-3p/ZEB1 axis. Cancer Manag Res. 2020;12:1587-99. doi: 10.2147/CMAR.S226409. PMID: 32184662; PMCID: PMC7060785.
20.Guo X, Wang Y. LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway. Cancer Med. 2020;9(14):5235-46. doi: 10.1002/cam4.3046. PMID: 32462698; PMCID: PMC7367632.
21.Cui H, Zhao J. LncRNA TMPO-AS1 serves as a ceRNA to promote osteosarcoma tumorigenesis by regulating miR-199a-5p/WNT7B axis. J Cell Biochem. 2020;121(3):2284-93. doi: 10.1002/jcb.29451. PMID: 31680323.
22.Ning X, Zhao J, He F, Yuan Y, Li B, Ruan J. Long non-coding RNA TMPO-AS1 facilitates chemoresistance and invasion in breast cancer by modulating the miR-1179/TRIM37 axis. Oncol Lett. 2021;22(1): 500. doi: 10.3892/ol.2021.12761. PMID: 33981362; PMCID: PMC8108256.
23.Zhu D, Lv W, Zhou X, He Y, Yao H, Yu Y et al. Long non-coding RNA TMPO-AS1 promotes tumor progression via sponging miR-140-5p in breast cancer. Exp Ther Med. 2021;21(1):17. doi: 10.3892/etm.2020. 9449. PMID: 33235626; PMCID: PMC7678596.
24.Yu X, Lin Q, Liu F, Yang F, Mao J, Chen X. LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p. Int J Immunopathol Pharmacol. 2020;34:2058738420958947. doi: 10.1177/20587 38420958947. PMID: 32969763; PMCID: PMC7520928.
25.Zarredar H, Ansarin K, Baradaran B, Ahdi Khosroshahi S, Farajnia S. Potential molecular targets in the treatment of lung cancer using siRNA technology. Cancer Invest. 2018;36(1):37-58. doi: 10.1080/ 07357907.2017.1416393. PMID: 29336624.
26.Luo H, Yang L, Liu C, Wang X, Dong Q, Liu L, et al. TMPO-AS1/miR-98-5p/EBF1 feedback loop contributes to the progression of bladder cancer. Int J Biochem Cell Biol. 2020;122:105702. doi: 10.1016/j.biocel.2020.105702. PMID: 32087328.
27.Xing B, Qiao XF, Qiu YH, Li X. TMPO-AS1 regulates the aggressiveness-associated traits of nasopharyngeal carcinoma cells through sponging miR-320a. Cancer Manag Res. 2021;13:415-25. doi: 10.2147/CMAR. S285113. PMID: 33488123; PMCID: PMC7815083.
28.Peng X, Yan J, Cheng F. LncRNA TMPO-AS1 up-regulates the expression of HIF-1α and promotes the malignant phenotypes of retinoblastoma cells via sponging miR-199a-5p. Pathol Res Pract. 2020;216(4):152853. doi: 10.1016/j.prp.2020.152853. PMID: 32139259.
29.Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 2021;13(17):4455. doi: 10.3390/cancers13174455. PMID: 34503265; PMCID: PMC8430879.
30.Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, et al. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci U S A. 2006;103(51):19472-7. doi: 10.1073/pnas.06046141 03. PMID: 17159154; PMCID: PMC1697829.
31.Ahn SK, Jung SY. Current biomarkers for precision medicine in breast cancer. Adv Exp Med Biol. 2021;1187:363-79. doi: 10.1007/978-981-32-9620-6_18. PMID: 33983588.